Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): Results from APeX-1 study

Autor: Anette Bygum, Panovska, V. G., Magerl, M., Farkas, H., Cicardi, M., Zanichelli, A., Cancian, M., Bova, M., Smith, W. B., Greve, J., Kinaciyan, T., Graff, J., Fang, L., Clemons, D., Joseph, K., Dobo, S., Mathis, A., Murray, S., Collis, P., Sheridan, W., Cornpropst, M., Aygoeren-Puersuen, E.

Publikováno v: Bygum, A, Panovska, V G, Magerl, M, Farkas, H, Cicardi, M, Zanichelli, A, Cancian, M, Bova, M, Smith, W B, Greve, J, Kinaciyan, T, Graff, J, Fang, L, Clemons, D, Joseph, K, Dobo, S, Mathis, A, Murray, S, Collis, P, Sheridan, W, Cornpropst, M & Aygoeren-Puersuen, E 2018, ' Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): Results from APeX-1 study ', Allergy, vol. 73, no. Suppl. 105, pp. 723 .
University of Southern Denmark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7fa7de2f2b28891bb7de7f1e50451e3e
https://portal.findresearcher.sdu.dk/da/publications/3b610051-4985-4010-a956-61a91b8dc0d2

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

BCX7353, a once-daily oral kallikrein inhibitor, is effective and safe in the prophylaxis of acute attacks in patients with hereditary angioedema: Attack-level analysis of the APeX-1 study

Autor: Aygören, E., Bygum, A., Steiner, U., Magerl, M., Panovska, V.G., Farkas, H., Huissoon, A., Graff, J., Lleonart, R., Rae, W., Aberer, W., Longhurst, H., Smith, W., Zanichelli, A., Cancian, M., Guilarte, M., Triggiani, M., Gompels, M., Fang, L., Cornpropst, M., Clemons, D., Collis, P., Dobo, S., Sheridan, W.P., Maurer, M., Cicardi, M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______610::4a1ab550b4615cfaab743ad6ac8f3bb3
https://publica.fraunhofer.de/handle/publica/252265

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY

Autor: Riedl, M., Lumry, W., Banerji, A., Aygoren-Pursun, E., Bernstein, J., Maurer, M., Cicardi, M., Christiansen, S., Zuraw, B., Dobo, S., Cornpropst, M., Iocca, H., Nagy, E., Murray, S., Collis, P., Sheridan, W., Johnston, D.

Publikováno v: In Annals of Allergy, Asthma & Immunology November 2019 123(5) Supplement:S28-S29